Breaking News Instant updates and real-time market news.

AAPL

Apple

$224.95

4.45 (2.02%)

, BBBY

Bed Bath & Beyond

$14.86

-3.94 (-20.96%)

16:18
09/27/18
09/27
16:18
09/27/18
16:18

Fly Intel: Wall Street's top stories for Thursday

Stocks opened in positive territory and remained there throughout the session. The gains today broke the recent slide by the market and kept the S&P on track for its best quarterly performance since 2013. The Nasdaq was the strongest of the indices, helped by shares of Apple (AAPL) that rose after a positive analyst initiation. Oil prices rose nearly 1% and closed back above $72 per barrel. ECONOMIC EVENTS: In the U.S., Q2 GDP growth was unrevised at 4.2% in the latest reading. Durable goods orders bounced 4.5% in August after dropping 1.2% in July. Initial jobless claims rose 12,000 to 214,000 in the week ended September 22. An index of pending home sales dropped 1.8% to 104.2 in August. The advance indicators report revealed a surprise widening in the August trade gap for goods thanks to a third consecutive big export drop alongside a surprising fourth consecutive big import gain. In Capitol Hill news, CNBC reported that the House of Representatives is expected to pass a three-bill legislative packaged known as Tax Reform 2.0 during votes on Thursday and Friday. While the package is not expected to make it through the Senate, some proposed adjustments to retirement savings could remain in play, according to the report. COMPANY NEWS: Shares of Bed Bath & Beyond (BBBY) dropped 21% following the company's Q2 earnings report, which Deutsche Bank analyst Mike Baker said showcased profit and margin declines "that were not only worse than consensus estimates but are decelerating versus recent quarters"... Shares of Conagra Brands (CAG) also fell 8.5% after the packaged foods maker reported worse than expected earnings and gave lower than expected quarterly guidance... Shares of Apple finished 2% higher after JPMorgan analyst Samik Chatterjee started coverage of the stock with a buy-equivalent rating and $272 price target, citing his view of the company's "compelling" services transformation, ripe installed base, and core capital deployment... Meanwhile, shares of Mack-Cali Realty (CLI) rose 4% after Bloomberg reported that activist investor Jonathan Litt said in a letter to Mack-Cali that his hedge fund learned of a potential suitor interested in making a fully financed bid for the company. MAJOR MOVERS: Among the noteworthy gainers was Cameco (CCJ), which surged 15% after it announced that the Tax Court of Canada has ruled in favor of the company in its dispute of the reassessments issued by Canada Revenue Agency for prior tax years. Also higher was Enphase Energy (ENPH), which gained 9% after it was chosen by Sunpro Solar to be its exclusive inverter supplier. Among the notable losers was Geron (GERN), which sunk 63% after its imetelstat collaboration with Johnson & Johnson's (JNJ) Jannsen was discontinued. Also lower was AngioDynamics (ANGO), which fell 11% after reporting earnings. INDEXES: The Dow rose 54.65, or 0.21%, to 26,439.93, the Nasdaq gained 51.60, or 0.65%, to 8,041.97, and the S&P 500 advanced 8.03, or 0.28%, to 2,914.00.

AAPL

Apple

$224.95

4.45 (2.02%)

BBBY

Bed Bath & Beyond

$14.86

-3.94 (-20.96%)

CAG

Conagra Brands

$33.00

-3.07 (-8.51%)

CLI

Mack-Cali Realty

$20.10

0.74 (3.82%)

CCJ

Cameco

$11.34

1.51 (15.36%)

ENPH

Enphase Energy

$4.94

0.41 (9.05%)

GERN

Geron

$2.31

-3.915 (-62.94%)

JNJ

Johnson & Johnson

$138.26

-0.01 (-0.01%)

ANGO

AngioDynamics

$21.66

-2.56 (-10.57%)

  • 27

    Sep

  • 27

    Sep

  • 27

    Sep

  • 01

    Oct

  • 16

    Oct

  • 28

    Oct

  • 15

    Nov

AAPL Apple
$224.95

4.45 (2.02%)

09/27/18
JPMS
09/27/18
INITIATION
Target $272
JPMS
Overweight
Apple initiated with an Overweight at JPMorgan
JPMorgan started Apple with an Overweight rating and $272 price target saying the company's Services transformation is "compelling."
09/27/18
JPMS
09/27/18
INITIATION
Target $272
JPMS
Overweight
JPMorgan sees 23% upside in Apple shares, starts with Overweight rating
JPMorgan analyst Samik Chatterjee initiated coverage of Apple with an Overweight rating and $272 price target. The shares closed yesterday down $1.77, or 1%, to $220.42. The analyst's price target implies 23% upside from current levels. While Apple's leadership position in the premium smartphone market is well understood by investors, its "faster-than-expected" transformation to a services business, "stronger-than-expected" price increases in the core iPhone business and earnings growth from stock buybacks can drive "considerable upside" to current share levels, Chatterjee tells investors in a research note. The analyst also believes Apple's "robust" high-single-digit growth in the installed base, which he says is a key contributor to Services revenue growth, has been underappreciated by investors.
09/27/18
09/27/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Apple (AAPL) initiated with an Overweight at JPMorgan. 2. UPS (UPS) initiated with a Sector Weight at KeyBanc. 3. Cigna (CI) initiated with an Overweight at Cantor Fitzgerald. 4. Restoration Robotics (HAIR) initiated with an Outperform at William Blair. 5. Alpine Immune Sciences (ALPN) initiated with an Overweight at Piper Jaffray. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/27/18
09/27/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. JPMORGAN STARTS APPLE AT OVERWEIGHT: JPMorgan analyst Samik Chatterjee initiated coverage of Apple (AAPL) with an Overweight rating and $272 price target. While Apple's leadership position in the premium smartphone market is well understood by investors, its "faster-than-expected" transformation to a services business, "stronger-than-expected" price increases in the core iPhone business and earnings growth from stock buybacks can drive "considerable upside" to current share levels, Chatterjee said. The analyst also believes Apple's "robust" high-single-digit growth in the installed base, which he says is a key contributor to services revenue growth, has been underappreciated by investors. LOOP CUTS APPLIED OPTOELECTRONICS TO SELL: Loop Capital analyst James Kisner downgraded Applied Optoelectronics (AAOI) to Sell from Hold and cut his price target for the shares to $20 from $45. The downgrade follows the analyst's industry checks which suggest the company is having product quality issues in 100G CWDM4 transceivers and that the pricing environment for 100G data center optics "remains very tough." It's possible that Applied Optoelectronics can get around the problem by procuring lasers externally, but this would obviously be negative for gross margin, the analyst said. NORTHLAND CUTS AMD TO MARKET PERFORM: Northland analyst Gus Richard said that while his thesis that AMD (AMD) will challenge Intel (INTC) has not changed, valuation has, prompting him to downgrade AMD shares to Market Perform from Outperform. He still sees AMD shares appreciating through year end, but Richard believes the stock price now reflects "irrational expectations." While downgrading his rating, Richard raised his price target on AMD shares to $30 from $26. STIFEL BOOSTS AMAZON PRICE TARGET TO STREET HIGH: Stifel analyst Scott Devitt increased his price target on Amazon (AMZN) shares to $2,525 from $2,020 primarily due to higher long-term revenue and margin expectations, driven by stronger than previously expected growth from Amazon's retail, cloud, and advertising businesses. He raised his 2019 advertising and other revenue forecast to $15.0B from $13.5B and hiked his 2020 view for the business to $20.2B from $17.6B. He increased his 2019 AWS revenue forecast to $36.6B from $35.4B and increased his 2020 view for AWS to $50.1B from $47.8B. Devitt also raised his 2019 and 2020 online stores revenue forecasts to $143.1B and $164.6, respectively, from $141.5B and $161.3B. He maintains a Buy rating on Amazon shares. CITI SAYS BED BATH & BEYOND TURNAROUND MAY BE TOO LITTLE, TOO LATE: Citi analyst Kate McShane lowered her price target for Bed Bath & Beyond (BBBY) to $13 from $16 and reiterated a Sell rating on the shares following the company's Q2 results. Management's turnaround plan "might be too little too late," McShane said in a post-earnings research note. In the near term, it's difficult to envision the company's initiatives "moving the needle in a meaningful way," McShane wrote. And over the long term, she finds it unclear which of the projects management will stick with.
BBBY Bed Bath & Beyond
$14.86

-3.94 (-20.96%)

09/27/18
JPMS
09/27/18
NO CHANGE
Target $14
JPMS
Underweight
Bed Bath & Beyond price target lowered to $14 from $16 at JPMorgan
JPMorgan analyst Christopher Horvers lowered his price target for Bed Bath & Beyond to $14 and reiterates an Underweight rating on the shares following the company's Q2 miss. The analyst continues to see Bed Bath's margin and sales being pressured in the near term as the company "plays catch-up in an intensely contested category." Further, he finds the company's negative comp in Q2 against a category that was up more than 5% in a "flush" consumer environment as "particularly concerning."
09/27/18
SBSH
09/27/18
NO CHANGE
Target $13
SBSH
Sell
Bed Bath turnaround plan 'might be too little too late,' says Citi
Citi analyst Kate McShane lowered her price target for Bed Bath & Beyond to $13 from $16 and reiterates a Sell rating on the shares following the company's Q2 results. Management's turnaround plan "might be too little too late," McShane tells investors in a post-earnings research note. In the near term, it's difficult to envision the company's initiatives "moving the needle in a meaningful way," McShane writes. And over the long term, she finds it unclear which of the projects management will stick with.
09/27/18
DBAB
09/27/18
NO CHANGE
Target $14
DBAB
Hold
Bed Bath & Beyond price target lowered to $14 from $17 at Deutsche Bank
Deutsche Bank analyst Mike Baker lowered his price target for Bed Bath & Beyond to $14 and keeps a Hold rating on the shares. In a post-earnings research note titled "Not Yet at Inflection Point," Baker says Baker's Q2 results missed expectations and showcased profit and margin declines "that were not only worse than consensus estimates but are decelerating versus recent quarters." The company continues to implement initiatives to turn the business around, "but that inflection point seems to be quite a way off," Baker contends. He keeps a Hold rating on Bed Bath & Beyond.
CAG Conagra Brands
$33.00

-3.07 (-8.51%)

06/29/18
RBCM
06/29/18
DOWNGRADE
Target $68
RBCM
Sector Perform
Pinnacle Foods downgraded to Sector Perform at RBC Capital after Conagra deal
RBC Capital analyst David Palmer downgraded Pinnacle Foods (PF) to Sector Perform from Outperform but raised his price target to $68 from $64 after its announced acquisition by Conagra Brands (CAG). Palmer notes that while the gross margin upside associated with this combination is greater than the initial synergy target, it will take some time to play out because it will come from changes in cost of goods sold.
08/21/18
08/21/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Conagra Brands (CAG) initiated with an Overweight at Stephens. 2. Vital Therapies (VTL) initiated with an Overweight at Cantor Fitzgerald. 3. Jefferies Financial Group (JEF) initiated with an Outperform at Keefe Bruyette. 4. Madison Square Garden (MSG) and MSG Networks (MSGN) were initiated with an Outperform at Imperial Capital. 5. Berry Petroleum (BRY) initiated with a Buy at Johnson Rice and Tudor Pickering. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/28/18
STFL
06/28/18
NO CHANGE
Target $42
STFL
Buy
Stifel still 'enamored' with potential for Conagra from Pinnacle combination
Stifel analyst Christopher Growe said the 7% slide in Conagra Brands (CAG) after the company announced its "long-awaited" deal to acquire Pinnacle Foods (PF) was perhaps due to less robust guidance around the potential for this acquisition. However, he remains "enamored" with the potential for the combination and keeps his Buy rating and $42 target price on Conagra, Growe tells investors.
08/20/18
SPHN
08/20/18
INITIATION
Target $45
SPHN
Overweight
Conagra Brands initiated with an Overweight at Stephens
Stephens analyst Farha Aslam initiated Conagra Brands (CAG) with an Overweight rating and $45 price target, contending that the management team put in place three years ago is transforming the company to reinvigorate growth and the recently announced deal to acquire Pinnacle Foods (PF) should help accelerate that transformation.
CLI Mack-Cali Realty
$20.10

0.74 (3.82%)

12/04/17
EVER
12/04/17
DOWNGRADE
EVER
In Line
Mack-Cali Realty downgraded to In Line from Outperform at Evercore ISI
02/26/18
STFL
02/26/18
UPGRADE
STFL
Hold
Mack-Cali Realty upgraded to Hold from Sell at Stifel
02/26/18
STFL
02/26/18
UPGRADE
Target $19
STFL
Hold
Mack-Cali Realty upgraded to Hold on activist potential at Stifel
Stifel analyst John Guinee upgraded Mack-Cali Realty to Hold from Sell with a $19 price target. At the current share price, the 40%-plus net asset value discount may attract activist investors, Guinee tells investors in a research note. He cites valuation and potential activism for his upgrade to Hold.
02/26/18
RHCO
02/26/18
NO CHANGE
Target $21
RHCO
Buy
Mack-Cali Realty price target lowered to $21 from $28 at SunTrust
SunTrust analyst Michael Lewis lowered his price target on Mack-Cali Realty to $21, saying the two quarters since his upgrade have been "painful". The analyst points to leasing, dispositions, and leverage challenges facing the company this year, but believes the reset of expectations for 2019 will position the stock favorably. Lewis keeps his Buy rating on Mack-Cali, noting its attractive 40% discount valuation relative to NAV.
CCJ Cameco
$11.34

1.51 (15.36%)

09/27/18
BMOC
09/27/18
UPGRADE
Target $16
BMOC
Outperform
Cameco upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst Alexander Pearce upgraded Cameco to Outperform from Market Perform and raised his price target to $16 from $14. The analyst cites the latest decision by the Tax Court of Canada in favor of the company in regards to its dispute of the reassessments ordered by Canada Revenue Agency, or CRA. Pearce contends that the decision, which had been a "significant overhang on the stock", could be worth as much as CAD 5 per share to its valuation, given that the company previously estimated related penalties of as much as CAD 2.15B.
07/27/18
BMOC
07/27/18
DOWNGRADE
Target $15
BMOC
Market Perform
Cameco downgraded to Market Perform from Outperform at BMO Capital
As reported earlier, BMO Capital analyst Alexander Pearce downgraded Cameco to Market Perform from Outperform and lowered his price target to $15 from $16. The analyst cites the company's indefinite suspension of operations at the world's largest uranium mine - McArthur River - noting the move "reinforces the message to utilities that future supplies are not guaranteed at current uranium prices". Pearce adds that while uranium price should be supported, it is a negative for Cameco earnings in the near term.
09/27/18
RAJA
09/27/18
UPGRADE
RAJA
Outperform
Cameco upgraded to Outperform from Market Perform at Raymond James
09/27/18
09/27/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Jernigan Capital (JCAP) upgraded to Buy from Hold at Jefferies with analyst George Hoglund saying he has an increasing near-term opportunity to acquire as many as 20 recently completed self-storage facilities in lease-up over the next 12-18 months. 2. Alaska Air (ALK) upgraded to Outperform from In-Line at Imperial Capital with analyst Michael Derchin saying the shares warrant a premium valuation due to the likelihood of industry-leading unit revenue growth in fiscal 2019. 3. Cameco (CCJ) upgraded to Outperform from Market Perform at Raymond James with analyst Alexander Pearce citing the latest decision by the Tax Court of Canada in favor of the company in regards to its dispute of the reassessments ordered by Canada Revenue Agency. 4. CarMax (KMX) upgraded to Outperform from Neutral at Baird. 5. KB Home (KBH) upgraded to Outperform from Market Perform at Raymond James. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ENPH Enphase Energy
$4.94

0.41 (9.05%)

09/19/18
ROTH
09/19/18
NO CHANGE
ROTH
Buy
Tariff exemption a 'meaningful positive' for SunPower, Enphase, says Roth
Roth Capital analyst Philip Shen tells investors in a research note that SunPower's (SPWR) exclusion from the 30% Section 201 import tariffs for its IBC cells and modules is a "meaningful positive" for the company, as with the exclusion, SunPower appears to be the only company to serve the U.S. resi market with tariff-free modules imported from outside the U.S., except for First Solar (FSLR), which does not serve the resi market. In addition, Shen views the news as a meaningful positive for Enphase (ENPH) given its exclusive relationship with SunPower, and says Enphase could benefit from increased volumes ahead.
09/18/18
VERF
09/18/18
NO CHANGE
VERF
Latest tariffs incremenally negative for SolarEdge, Enphase, says Vertical Group
Vertical Group analyst Gordon Johnson said the latest round of tariffs being imposed by the U.S. on Chinese imports are an incremental negative for solar inverter companies with owned and/or outsourced manufacturing capacity in China, such as SolarEdge (SEDG) and Enphase Energy (ENPH). He also thinks the escalating U.S. trade war with China offers a competitive advantage to European-based manufacturers that have recently converted their technology, such as ABB (ABB). At the very least, inverter prices are set to increase at least 10% if distributors do not shift demand over to more traditional string-based suppliers, Johnson tells investors.
08/01/18
RILY
08/01/18
NO CHANGE
Target $7.5
RILY
Buy
Enphase Energy weakness a buying opportunity, says B. Riley FBR
B. Riley FBR analyst Carter Driscoll views the post-earnings weakness in shares of Enphase Energy as a buying opportunity. Enphase rebuked the short report and the upcoming analyst day, which will unveil a differentiated iQ8 microinverter, provides catalysts, Driscoll tells investors in a research note. He keeps a Buy rating on the shares with a $7.50 price target.
06/15/18
ROTH
06/15/18
NO CHANGE
ROTH
Enphase, SolarEdge inverters won't be subject to 301 tariffs, says Roth Capital
After the U.S. Trade Representative released two lists of products that will be subject to 25% tariffs under the Section 301 investigation, Roth Capital analyst Philip Shen noted that the lists did not include solar inverters, cells, or modules. He does not believe imported inverters from Enphase Energy (ENPH), SolarEdge (SEDG) and others will be subject to 301 tariffs, though he notes that solar cells and modules will continue to be impacted by the Section 201 and AD/CVD tariffs. Other publicly traded companies in the solar space include Canadian Solar (CSIQ), First Solar (FSLR), JA Solar (JASO), SunPower (SPWR), Trina Solar (TSL) and Yingli Green Energy (YGE).
GERN Geron
$2.31

-3.915 (-62.94%)

03/19/18
PIPR
03/19/18
NO CHANGE
Target $7
PIPR
Overweight
Geron price target raised to $7 from $5 at Piper Jaffray
Piper Jaffray analyst Charles Duncan raised his price target for Geron to $7 after the company this morning reported year-end 2017 cash of $109M and provided an update on its IMerge and IMbark studies. The analyst projects the current cash will fund Geron's operations into 2020. He's encouraged by the update on the IMbark study in myelofibrosis and reiterates an Overweight rating on the shares.
07/05/18
RILY
07/05/18
INITIATION
Target $5.75
RILY
Buy
Geron initiated with a Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico started Geron with a Buy rating and $5.75 price target.
JNJ Johnson & Johnson
$138.26

-0.01 (-0.01%)

08/27/18
WBLR
08/27/18
NO CHANGE
WBLR
Outperform
Mariner failure removes potential Portola competition, says William Blair
William Blair analyst Matt Phipps says that while the failure of Johnson & Johnson's (JNJ) Mariner trial removes potential competition Portola Pharmaceuticals' (PTLA) Bevyxxa, which is positive, "significant work" is still needed to gain adoption of Bevyxxa in the United States. As such, the Mariner results do not significantly alter the near-term headwinds for Bevyxxa, Phipps tells investors in a research note. The analyst believes getting beyond the Mariner presentation allows investors to focus on the opportunity for Andexxa, which he still thinks is "significant." He points out that Portola remains on track to file the prior approval supplement for the second-generation manufacturing process of Andexxa in the coming days, which would provide sufficient supply for 1,000 hospitals in the United States and expansion into Europe. Phipps keeps an Outperform rating on Portola Pharmaceuticals, which is up 5% to $29.60 in premarket trading.
08/27/18
MSCO
08/27/18
NO CHANGE
MSCO
Equal Weight
Portola may be up 'somewhat' on Xarelto trial failure, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted the failure of Johnson & Johnson's (JNJ)MARINER study, which was examining Xarelto, a competing anticogulant to Portola's (PTLA) BevyxXa. MARINER's failure to demonstrate a statistically significant result of reducing symptomatic VTE or death due to VTE is expected by Harrison to send Portola shares up "somewhat," but he believes most investors had already lowered their expectations for the BevyxXa franchise after the Q2 report, making the impact modest. He maintains an Equal Weight rating on Portola shares, which are up 3% to $29 per share in early trading.
09/14/18
WELS
09/14/18
NO CHANGE
Target $160
WELS
Outperform
Johnson & Johnson price target raised to $160 from $150 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised his price target for Johnson & Johnson to $160 after the company hosted an investor call to provide an update on its Pharmaceuticals business. The analyst heard no strategic change to the business saying J&J maintains focus on its six key therapeutic areas and remains agnostic to the source of innovation. While the company did not provide 2019 guidance, management's tone came across as confident in the business outlook, Biegelsen tells investors in a research note. He keeps an Outperform rating on Johnson & Johnson.
08/27/18
08/27/18
UPGRADE
Target $34

Neutral
Portola Pharmaceuticals upgraded to Neutral as MARINER sinks at Credit Suisse
As previously reported, Credit Suisse analyst Vamil Divan upgraded Portola Pharmaceuticals (PTLA) to Neutral from Underperform after Johnson & Johnson (JNJ)/Bayer (BAYRY) presented disappointing data for Xarelto in the acute medically ill population at ESC. The analyst notes that the data avoids a worst case scenario for Portola's Bevyxxa by essentially removing a potentially strong competitor, but does put the pressure on Portola to successfully change medical practice on its own, without help from a larger player such as Johnson & Johnson. Divan also raised his price target on Portola's shares to $34 from $28.
ANGO AngioDynamics
$21.66

-2.56 (-10.57%)

07/12/18
ADAM
07/12/18
NO CHANGE
Target $20
ADAM
Hold
AngioDynamics price target raised to $20 from $17 at Canaccord
Canaccord analyst Jason Mills reiterated a Hold rating on AngioDynamics and raised his price target to $20 following the company's "fairly in-line" quarter, telling investors in a research note that lack of upside, along with a "somewhat lackluster" guide for FY19 drove a sell-off in the stock post print. While Mills thinks the company is better positioned operationally today than it was two years ago when CEO Clemmer took over the helm, growth remains the key piece missing from the story. The analyst believes NanoKnife is the company's biggest opportunity and potential growth driver, but thinks it will be a few years before it can provide meaningful contributions to AngioDynamics' top line.
07/11/18
RAJA
07/11/18
DOWNGRADE
RAJA
Market Perform
AngioDynamics downgraded to Market Perform from Outperform at Raymond James
04/03/18
04/03/18
UPGRADE
Target $21

Outperform
AngioDynamics upgraded to Outperform at Raymond James
As previously reported, Raymond James analyst Jayson Bedford upgraded AngioDynamics to Outperform from Market Perform, with a $21 price target, based on a combination of attractive valuation on a stock that has been a chronic underperformer, an inflection in gross margins, which offers cushion to his earnings estimates, and his view that management should engage in more active portfolio management, which has the potential to unlock value in a stock.
04/03/18
RAJA
04/03/18
UPGRADE
RAJA
Outperform
AngioDynamics upgraded to Outperform from Market Perform at Raymond James

TODAY'S FREE FLY STORIES

03:00
11/21/18
11/21
03:00
11/21/18
03:00
General news
FX Action: USD-CAD has steadied »

FX Action: USD-CAD has…

02:35
11/21/18
11/21
02:35
11/21/18
02:35
General news
FX Update: The Dollar majors have traded mixed »

FX Update: The Dollar…

02:00
11/21/18
11/21
02:00
11/21/18
02:00
General news
FX Action: USD-JPY has traded moderately firmer »

FX Action: USD-JPY has…

01:45
11/21/18
11/21
01:45
11/21/18
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

MDT

Medtronic

$92.31

1.91 (2.11%)

20:48
11/20/18
11/20
20:48
11/20/18
20:48
Recommendations
Medtronic analyst commentary at Piper Jaffray »

Medtronic in the midst of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

RDY

Dr. Reddy's

$36.48

1.19 (3.37%)

20:44
11/20/18
11/20
20:44
11/20/18
20:44
Hot Stocks
Dr. Reddy's announces favorable outcome in Buprenorphine and Naloxone litigation »

Dr. Reddy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCCO

Southern Copper

$35.63

-1.615 (-4.34%)

20:30
11/20/18
11/20
20:30
11/20/18
20:30
Upgrade
Southern Copper rating change at Bradesco »

Southern Copper upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBH

KB Home

$19.84

0.37 (1.90%)

20:17
11/20/18
11/20
20:17
11/20/18
20:17
Hot Stocks
KB Home expands into Seattle housing market »

KB Home announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDR

Cloudera

$10.69

-0.545 (-4.85%)

20:16
11/20/18
11/20
20:16
11/20/18
20:16
Hot Stocks
Cloudera partners with Bank Rakyat Indonesia »

Cloudera announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

AAPL

Apple

$177.10

-8.7 (-4.68%)

19:44
11/20/18
11/20
19:44
11/20/18
19:44
Periodicals
Apple acquires AI software firm Silk Labs, The Information reports »

Apple is said to have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

NVT

nVent Electric

$24.18

-0.35 (-1.43%)

19:20
11/20/18
11/20
19:20
11/20/18
19:20
Initiation
nVent Electric initiated at Vertical Research »

nVent Electric initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

FB

Facebook

$132.47

0.85 (0.65%)

19:13
11/20/18
11/20
19:13
11/20/18
19:13
Periodicals
Russia's FAN sues Facebook, claims to be legitimate news outlet, Reuters says »

Facebook is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

CMCSA

Comcast

$36.75

-1.44 (-3.77%)

, CMCSK

Comcast

$0.00

(0.00%)

18:58
11/20/18
11/20
18:58
11/20/18
18:58
Periodicals
Megyn Kelly seen to leave NBC News with entirety of $69M deal, WSJ says »

Megyn Kelly is…

CMCSA

Comcast

$36.75

-1.44 (-3.77%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

FL

Foot Locker

$46.10

-2.69 (-5.51%)

, ADSK

Autodesk

$122.99

-2.76 (-2.19%)

18:56
11/20/18
11/20
18:56
11/20/18
18:56
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Foot…

FL

Foot Locker

$46.10

-2.69 (-5.51%)

ADSK

Autodesk

$122.99

-2.76 (-2.19%)

BJ

BJ's Wholesale

$19.85

-0.22 (-1.10%)

KEYS

Keysight Technologies

$54.35

-1.23 (-2.21%)

CPRT

Copart

$47.30

-1.255 (-2.58%)

VNET

21Vianet

$11.20

-0.1 (-0.88%)

GPS

Gap

$24.65

-0.79 (-3.11%)

BILI

Bilibili

$13.61

0.575 (4.41%)

DXCM

DexCom

$119.89

-1.34 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 26

    Nov

  • 27

    Nov

  • 04

    Dec

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 03

    Mar

AAPL

Apple

$177.10

-8.7 (-4.68%)

18:46
11/20/18
11/20
18:46
11/20/18
18:46
Periodicals
Apple in discussions to give vets access to electronic medical records, WSJ says »

Apple is in talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

FB

Facebook

$132.47

0.85 (0.65%)

18:32
11/20/18
11/20
18:32
11/20/18
18:32
Periodicals
Facebook ads system was down today for some users, Bloomberg says »

Facebook's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

EMCI

EMC Insurance

$32.33

1.1 (3.52%)

18:28
11/20/18
11/20
18:28
11/20/18
18:28
Hot Stocks
EMC Insurance announces receipt of proposal from EMCC to buy all of its shares »

EMC Insurance announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEX

Emerald Expositions Events

$11.09

0.17 (1.56%)

18:26
11/20/18
11/20
18:26
11/20/18
18:26
Hot Stocks
Emerald Expositions Events announces $20M share repurchase program »

The company anticipates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIVN

LivaNova

$98.00

-22.28 (-18.52%)

18:26
11/20/18
11/20
18:26
11/20/18
18:26
Recommendations
LivaNova analyst commentary at Piper Jaffray »

LivaNova price decline on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 27

    Nov

BKH

Black Hills

$64.40

0.92 (1.45%)

18:24
11/20/18
11/20
18:24
11/20/18
18:24
Hot Stocks
Black Hills Energy receives approval to construct $54M gas pipeline in Wyoming »

Black Hills announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,026.00

7 (0.69%)

, GOOGL

Alphabet Class A

$1,031.22

4.99 (0.49%)

18:19
11/20/18
11/20
18:19
11/20/18
18:19
Periodicals
Google expands Moffett Park presence again, SVBJ says »

Google is once again…

GOOG

Alphabet

$1,026.00

7 (0.69%)

GOOGL

Alphabet Class A

$1,031.22

4.99 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 03

    Mar

SE

Sea Limited

$12.18

-0.52 (-4.09%)

18:04
11/20/18
11/20
18:04
11/20/18
18:04
Earnings
Sea Limited reports Q3 net loss ($237.6M) vs. ($127.1M) last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BILI

Bilibili

$13.61

0.575 (4.41%)

18:03
11/20/18
11/20
18:03
11/20/18
18:03
Earnings
Bilibili reports Q3 revenue $157.1M, consensus $146.72M »

Reports Q3 adjusted net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

LTM

Latam Airlines

$9.24

-0.4 (-4.15%)

18:01
11/20/18
11/20
18:01
11/20/18
18:01
Hot Stocks
Breaking Hot Stocks news story on Latam Airlines »

LATAM Airlines reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CE

Celanese

$100.26

-1.53 (-1.50%)

18:01
11/20/18
11/20
18:01
11/20/18
18:01
Hot Stocks
Celanese increases Fortron polyphenylene sulphide price by 85c per kg »

The price increases will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.